Doctors prescribe Evenity (romosozumab-aqqg) to treat postmenopausal osteoporosis. The drug falls under Medicare Part B coverage because a healthcare professional needs to administer it. You may get ...
THOUSAND OAKS, Calif. and BRUSSELS, April 1, 2017/ PRNewswire/-- Amgen and UCB today announced results from the fourth year of a Phase 2 study showing the efficacy and safety of a second course of ...
The European Medicines Agency has accepted UCB and Amgen’s submission seeking approval for use of bone-boosting drug Evenity in post-menopausal women and in men at increased risk of fracture. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results